Edasalonexent
Modify Date: 2024-01-14 19:35:45
Edasalonexent structure
|
Common Name | Edasalonexent | ||
|---|---|---|---|---|
| CAS Number | 1204317-86-1 | Molecular Weight | 490.677 | |
| Density | 1.0±0.1 g/cm3 | Boiling Point | 716.8±60.0 °C at 760 mmHg | |
| Molecular Formula | C31H42N2O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 387.3±32.9 °C | |
Use of EdasalonexentEdasalonexent is an orally bioavailable NF-κB inhibitor. |
| Name | edasalonexent |
|---|---|
| Synonym | More Synonyms |
| Description | Edasalonexent is an orally bioavailable NF-κB inhibitor. |
|---|---|
| Related Catalog | |
| Target |
NF-κB[1] |
| In Vitro | Edasalonexent is an orally administered small molecule in which salicylic acid and docosahexaenoic acid (DHA) are covalently conjugated through an ethylenediamine linker and that is designed to synergistically leverage the ability of both of these compounds to inhibit NF-κB. Edasalonexent significantly inhibits NF-κB p65-dependent inflammatory responses as well as downstream proinflammatory genes modulated by p65 in the golden retriever duchenne muscular dystrophy (DMD) model[2]. |
| In Vivo | The treatment of mdx mice with Edasalonexent for 20 weeks results in reduced susceptibility of the extensor digitorum longus muscle to eccentric contraction-induced injury[1]. |
| Animal Admin | Mice[1] Male mdx or WT mice are used. Drug treatment protocols entail feeding individually housed mice a specialty control chow or chow containing either CAT-1041 or Edasalonexent (0.75% w/w) ad libitum starting at 4 weeks of age. Average drug consumption typically ranges between 0.75 and 1 mg/g body weight per day. The 24-hour plasma exposure at this dosage is 450ng hr/mL for Edasalonexent[1]. |
| References |
| Density | 1.0±0.1 g/cm3 |
|---|---|
| Boiling Point | 716.8±60.0 °C at 760 mmHg |
| Molecular Formula | C31H42N2O3 |
| Molecular Weight | 490.677 |
| Flash Point | 387.3±32.9 °C |
| Exact Mass | 490.319550 |
| LogP | 7.31 |
| Vapour Pressure | 0.0±2.4 mmHg at 25°C |
| Index of Refraction | 1.554 |
| Storage condition | 2-8℃ |
| AF3Z6434KS |
| Benzamide, 2-hydroxy-N-[2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-1-oxo-4,7,10,13,16,19-docosahexaen-1-yl]amino]ethyl]- |
| edasalonexent |
| N-{2-[(4Z,7Z,10Z,13Z,16Z,19Z)-4,7,10,13,16,19-Docosahexaenoylamino]ethyl}-2-hydroxybenzamide |